|
**Overview**: **Dengue and Chikungunya RNA PCR Test****Introduction**: The Dengue or Chikungunya RNA PCR Test is a diagnostic tool designed to detect RNA of dengue and chikungunya viruses in plasma samples, facilitating the diagnosis of viral infections. Associated with dengue fever or chikungunya arthritis, these infectious diseases present with fever, joint pain, and severe complications like hemorrhagic fever if untreated, particularly in individuals in endemic areas or with mosquito exposure. Per the 2023 World Health Organization guidelines, the test employs polymerase chain reaction (PCR) technology, delivering results within 3-5 days with high sensitivity and specificity, making it a valuable tool for initial screening in molecular pathology settings. This diagnostic falls under molecular pathology and targets individuals with febrile or arthritic symptoms, addressing the challenge of early detection to guide supportive care or antiviral therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its plasma-based approach ensures rapid detection.**Other Names**: Dengue & Chikungunya PCR Test.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by various molecular labs, this test advanced viral detection by leveraging PCR for rapid RNA identification.**Purpose**: The test detects dengue and chikungunya virus RNA to guide viral infection diagnosis, assess infectious status, and inform treatment and prevention strategies.**Test Parameters**: Presence of dengue virus RNA and chikungunya virus RNA, detected with high specificity to indicate active infection, typically detectable in plasma at elevated levels during viremia.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fever, joint pain, or recent mosquito bites.**Specimen**: Plasma 2-4 mL, collected using EDTA tubes, transported within 24 hours to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling in a cool environment to preserve RNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade RNA, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on fever, joint pain, prior viral infections, or family history of infectious disease, as well as any recent travel or mosquito exposure.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including hemorrhagic fever, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves RNA extraction, PCR amplification, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 3-5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent antiviral use can affect results. Correlation with serology or clinical evaluation is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible dengue or chikungunya infection, necessitating further investigation like serology or infectious disease consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the viremic phase.**Specialist Consultation**: Infectious disease specialists should be consulted for case management, treatment planning, and coordination with disease control programs.**Additional Supporting Tests**: NS1 antigen, IgM/IgG, or clinical assessment for confirmation.**Test Limitations**: The test may produce false negatives in late infection or false positives in cross-reactivity, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: WHO Guidelines 2023, Journal of Virology 2024, Molecular Pathology 2025. |
